The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial
Juan José Rodríguez‐Sevilla(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center), Xavier Calvo(Hospital Del Mar), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Kelly S. Chien, Hui Yang(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Vera Ademà(Cleveland Clinic), Feiyang Ma(Northwestern University), Kristy Bodden(The University of Texas MD Anderson Cancer Center), Joby Joseph(The University of Texas MD Anderson Cancer Center)
Cited by 18
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Telomere dysfunction induces metabolic and mitochondrial compromise
|Nature|2011|1.3k